cancer clinical trial

Anetumab Ravtansine Fails to Show Improvement of Progression-Free Survival in Mesothelioma

In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to improve progression-free survival in mesothelioma patients.
“Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, Executive Vice President and […]


Results Show Encouraging Survival Data: Nintedanib for Mesothelioma

On June 5, Anna Nowak, MD, PhD, of the University of Western Australia and member of the Meso Foundation’s Science Advisory Board, presented phase II results from LUME-Meso, a mesothelioma clinical trial sponsored by Boehringer Ingelheim, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
LUME-Meso is a randomized, double-blind, placebo-controlled trial evaluating […]


BREAKING NEWS FROM ASCO: Promising Results Released from Mesothelioma Clinical Trial

This morning, Arnaud Scherpereel, MD, PhD, head of the Pulmonary and Thoracic Oncology Department at the University Hospital of Lille in France, presented the results of the IFCT-1501 MAPS-2 clinical trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study was sponsored by the French Cooperative Thoracic Intergroup (IFCT) with drugs and […]


Facing Mesothelioma One Journal Entry at a Time: Part Nine

Tara DeAugustinis has been battling pleural mesothelioma since diagnosed in early 2016 at the age of 45. She and her husband, Rich, have maintained a personal website documenting her journey with the disease via journal entries, and they have decided to share their story with the mesothelioma community. To read part eight of this story, […]